Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.

Cells · 2020 · PMC7408116 · PMID 32650421

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

A selective THR-β agonist, resmetirom, has demonstrated a highly significant reduction in hepatic fat and decreased hepatic inflammation in NASH patients following a 36-week treatment [ 219 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.